Highlights

  • Biome Australia shares rose 0.62% to AUD 0.33 on 27 April 2026 following a new patent application update.
  • The company filed its first patent for proprietary probiotic strain BMB18.
  • Pre-clinical studies indicate BMB18 demonstrates differentiated functional characteristics.
  • A 240-participant human clinical trial is expected to commence in Q4 FY26.
  • The initiative marks Biome’s entry into intellectual property-led development.
  • The company maintains a direct pathway to market through its Activated Probiotics brand.

Biome Australia Ltd (ASX:BIO) shares increased 0.62% to AUD 0.33 during the afternoon session on 27 April 2026, following the release of an update outlining the filing of its first patent application for a proprietary probiotic strain. Despite today’s modest gain, the stock remains down approximately 25.68% over the past year, reflecting broader performance trends while investors assess the company’s ongoing strategic developments.

Biome Australia is a microbiome health company focused on developing, licensing, and commercialising evidence-based probiotics and complementary medicines. Incorporated in 2018, the company distributes its products both domestically and internationally, primarily through practitioner-led channels. Its flagship Activated Probiotics® range is supported by clinical research and designed to address a variety of health conditions, including gut health, immune function, and metabolic support.

Patent Filing Marks Entry into IP Development Strategy

The key development disclosed in the latest update is the filing of Biome’s inaugural patent application for its proprietary probiotic strain, BMB18. This milestone represents the company’s initial step into building an intellectual property portfolio aimed at supporting long-term innovation and differentiation.

BMB18 is the first outcome of Biome’s broader strategy to develop next-generation probiotic solutions that extend beyond conventional formulations. The company has undertaken detailed strain characterisation and development processes, laying the groundwork for further exploration of proprietary strains across multiple therapeutic applications.

This approach is supported by advanced methodologies used to evaluate functional characteristics of probiotic strains. According to the company, pre-clinical (in-vitro) studies have already demonstrated that BMB18 exhibits differentiated functional properties. These include potential immune system modulation, support for intestinal barrier function, and antioxidant activity.

The patent filing itself is intended to strengthen Biome’s competitive positioning while establishing a structured pathway for intellectual property development. The company has indicated that this initiative will serve as a platform for expanding its pipeline of proprietary strains over time.

Clinical Trial to Advance Evidence Base

In addition to the patent filing, Biome provided an update on the progress of its first human clinical trial involving the BMB18 strain. The study has received the necessary ethics approvals and is expected to commence in partnership with La Trobe University in the fourth quarter of FY26.

The trial is designed as a randomised, double-blind, placebo-controlled study and aims to recruit 240 participants. This structure is intended to generate high-quality clinical data that can support the evaluation of BMB18’s therapeutic potential.

The outcomes of this trial are expected to contribute to Biome’s broader data set on the strain, which will inform both product development and future commercialisation strategies. The company noted that the results may support the integration of BMB18 into its existing product pipeline or enable standalone product development, depending on clinical findings.

BMB18 has also been registered with the DSMZ strain bank in Germany, an internationally recognised repository used for strain identification and reference. This registration supports both the patent process and the scientific validation of the strain.

Building a Broader Intellectual Property Platform

Biome’s latest update highlights the beginning of a broader intellectual property development strategy. The company is working to establish systematic capabilities in strain identification, characterisation, and validation, which are essential components of developing proprietary probiotic solutions.

Future activities will focus on identifying and evaluating additional strain candidates, with the goal of building a portfolio of assets that can differentiate Biome’s offerings in the practitioner market. This approach aligns with the company’s emphasis on evidence-based products supported by clinical research.

The development of proprietary strains also provides potential opportunities for premium positioning, particularly in practitioner-led distribution channels where clinical evidence and product differentiation are key considerations.

Commercialisation Pathway Through Established Channels

Biome emphasised that its existing distribution network provides a direct pathway to market for future products derived from its intellectual property initiatives. The company’s Activated Probiotics brand is already established within practitioner networks, offering access to healthcare professionals who recommend evidence-based solutions to patients.

This practitioner-led model supports the introduction of new products backed by clinical data, aligning with the company’s focus on scientific validation. The company indicated that BMB18 is being evaluated for potential inclusion in its current product development pipeline, with commercialisation strategies to be determined based on clinical outcomes and market considerations.

Potential approaches may include standalone products or formulations combining BMB18 with other probiotic strains, depending on practitioner demand and therapeutic applications.

Management Commentary and Strategic Direction

Biome’s Managing Director and Founder, Blair Vega Norfolk, described the patent filing as an important milestone in the company’s development. The company highlighted that BMB18’s functional profile, combined with safety and characterisation data, positions it as a candidate for future probiotic solutions aimed at health practitioners and patients.

The company also noted that the clinical trial with La Trobe University introduces an additional dimension to its growth strategy, linking intellectual property development with clinical validation. This approach reflects Biome’s objective of building sustainable IP assets while maintaining a focus on practitioner education and clinical efficacy.

The BMB18 initiative is positioned as the first step in a broader journey of intellectual property exploration, which the company expects will contribute to differentiating its product offerings over time.

What This Means for Investors?

Biome Australia’s latest update outlines a strategic shift towards intellectual property development, beginning with the patent application for the BMB18 probiotic strain. The combination of pre-clinical validation, planned clinical trials, and integration with existing commercial channels provides a structured pathway for future product development.

While the immediate financial impact of the update may be limited, the patent filing and associated clinical program represent foundational steps in building a differentiated product portfolio. The upcoming clinical trial, expected to commence in Q4 FY26, will be a key milestone in assessing the commercial potential of BMB18.

The share price movement on 27 April 2026 reflects a measured market response to this development, with investors likely to monitor further progress in clinical outcomes and intellectual property expansion.